Quality-of-life-adjusted survival for comparing cancer treatments. A commentary on twist and q-twist
- 1 February 1991
- Vol. 67 (S3) , 851-854
- https://doi.org/10.1002/1097-0142(19910201)67:3+<851::aid-cncr2820671417>3.0.co;2-g
Abstract
In chronic disease situations where treatment comparisons favor no particular therapy, or where definitive outcome requires a considerable follow-up period, it is useful to have additional and perhaps intermediate endpoints of relevant clinical significance to compare treatments. One such endpoint is Time Without Symptoms and Toxicity (TWiST) which, together with Q-TWiST, attempts to address the quality of life of patients receiving the competing regimens. This paper provides a commentary on these techniques with an emphasis on the problems inherent in implementing Q-TWiST, a measure that attempts to incorporate patient value preferences into TWiST. It is argued that while Q-TWiST is intuitively appealing in the clinical setting, there are formidable design and psychometric hurdles that must be overcome to fully operationalize the concept.Keywords
This publication has 3 references indexed in Scilit:
- Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis.Journal of Clinical Oncology, 1989
- A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer.Journal of Clinical Oncology, 1986
- Work, Social, Recreation, Family, and Physical StatusCancer, 1984